Cycle Pharmaceuticals announces the launch of PHYRAGO, its first oncology product in the US. PHYRAGO is launched in ...

Various symptoms indicate chronic myelogenous leukemia (CML) has progressed from one phase to another. These include an increase in leukemia cells, a change in a person’s platelet count, and worsening ...

When oral medicines for Chronic Myeloid Leukemia (CML) first became available, they dramatically changed what it meant to ...

Newly published data suggests most patients are opting for second- or third-generation tyrosine kinase inhibitors instead of a generic form of imatinib. Patients with chronic myelogenous leukemia (CML ...

Chronic myeloid leukemia (CML), also known as chronic myelogenous leukemia, is a type of cancer. It starts in blood-forming cells within the bone marrow, creating leukemia cells. These cells transfer ...

The FDA has issued a complete response letter (CRL) to a new drug application (NDA) for Dasynoc for the treatment of chronic ...

A CML diagnosis, often striking young Indian adults, is now more manageable. This guide emphasizes empowering patients by ...

Patient adherence to tyrosine kinase inhibitors (TKIs) ranges widely—from 19% to 100%—according to several studies. Most participants in the current study believed in the efficacy of their medication, ...

Lindsay A. Rein, MD, reviews exciting data presented at this year’s ASH meeting, focusing on chronic myeloid leukemia (CML) and the recent approval of asciminib, a novel agent for first-, second-, and ...

To evaluate the role of Hh signalling in CML, Reya and colleagues developed mice that lacked expression of smoothened (SMO), the transmembrane protein that transmits Hh signals, in haematopoietic ...

CML Microsystems ( ($GB:CML) ) has issued an announcement. CML Microsystems has announced the issuance of new ordinary shares to Non-Executive ...

CML Microsystems plc (LON:CML) shareholders (or potential shareholders) will be happy to see that the Non-Executive Director, Nathan Zommer, recently bought a whopping UK£1.5m worth of stock, at a ...